Skip to main content
GENFLOW BIOSCIENCES PLC logo

GENFLOW BIOSCIENCES PLC — Investor Relations & Filings

Ticker · GENF ISIN · GB00BP2C3V08 LEI · 213800HVOFXRXVEGDN62 IL Professional, scientific and technical activities
Open in API
Filings indexed 142 across all filing types
Latest filing 2025-05-15 Regulatory Filings
Country GB United Kingdom
Listing IL GENF

About GENFLOW BIOSCIENCES PLC

https://genflowbio.com/

Genflow Biosciences PLC is a biotechnology company developing gene therapies that target the aging process. The company's primary mission is to slow or halt aging and reduce the incidence of age-related diseases in both humans and dogs, thereby extending healthspan. Its lead therapeutic candidate, GF-1002, is a gene therapy that delivers a centenarian variant of the Sirtuin 6 (SIRT6) gene. This specific gene variant has been identified in individuals who live to 100 years or more and has demonstrated promising results in pre-clinical studies.

Recent filings

Filing Released Lang Actions
Key SIRT6 Patent Application
Regulatory Filings Classification · 99% confidence The document is a press release distributed via RNS (London Stock Exchange's regulatory news service), indicated by the 'RNS Number' and the footer mentioning 'Reach, the non-regulatory press release distribution service of RNS'. The content announces progress on a patent application ('Genflow Biosciences Announces Progress of Key SIRT6 Patent Application in Japan'). This type of announcement, which is a general corporate update distributed through a regulatory wire service but does not fit neatly into specific financial reporting categories (like 10-K, ER, or DIV), is best classified as a general Regulatory Filing or Announcement. Since it is a specific corporate update distributed via RNS, and RNS is listed as the fallback for miscellaneous filings, the most appropriate code is RNS, unless a more specific category applies. It is not an Earnings Release (ER), a Capital Update (CAP), or a Director's Dealing (DIRS). Therefore, RNS is the correct classification for this general regulatory news item.
2025-05-15 English
Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is identified by the RNS Number (2844I) and explicitly states it is a 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically when a threshold is crossed or reached (Section 2 and 5). This directly corresponds to the definition of a Major Shareholding Notification. Although it is distributed via RNS, the specific content dictates the classification over the general RNS category.
2025-05-12 English
Share Subscription, Director's Dealing and Update
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement from Genflow Biosciences PLC regarding a capital raise of £500,000 through a share subscription, which also includes a mandatory disclosure of a director's dealing (PDMR notification) and an update on clinical trial progress. While it contains elements of director dealings and clinical updates, the primary purpose is the announcement of a new share issuance and capital raise. According to the filing definitions, 'SHA' (Share Issue/Capital Change) is the most accurate classification for announcements regarding new share issues and capital changes.
2025-05-09 English
Annual financial statements 2024
Annual Report Classification · 100% confidence The document is titled 'Annual Report and Financial Statements for the Year Ended 31 December 2024' and contains detailed sections typical of an annual report, including Chairperson's Statement, Strategic Report, Directors' Report, Corporate Governance Report, Audit Committee Report, Independent Auditor's Report, and full financial statements such as Statement of Financial Position, Statement of Comprehensive Income, and Notes to the Financial Statements. The content includes comprehensive financial data, management discussion, strategic updates, and audit information, all consistent with a full annual report. The document length is substantial (15,000 characters), indicating it is the full report rather than an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2024
2025-05-07 English
Annual financial statements 2024
Annual Report Classification · 100% confidence The document is explicitly titled 'GENFLOW BIOSCIENCES PLC ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024'. It contains comprehensive sections typical of an annual report, including the Chairperson's Report, Strategic Report, Directors' Report, Corporate Governance Report, Independent Auditor's Report, and full financial statements (Statement of Financial Position, Comprehensive Income, Cash Flows, and Notes). It is not an announcement or a summary, but the full statutory report. FY 2024
2025-05-07 English
Final Results
Annual Report Classification · 95% confidence The document is a 'Final Results' announcement from Genflow Biosciences PLC for the year ended 31 December 2024. It contains detailed financial highlights, a Chairperson's report, a Strategic report, and financial performance data. While it mentions that the full Annual Report will be available on the website, the document itself provides the substantive financial results, management commentary, and operational updates, which qualifies it as an Annual Report (10-K) equivalent for a UK-listed company. FY 2024
2025-04-30 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.